Silence Therapeutics Share Price (SLN)
| Bid price | 1.50 | Open price | 1.47 |
|---|---|---|---|
| Ask price | 1.65 | Prev close | 1.58 |
| High price | 1.61 | Spread | 9.09% |
| Low price | 1.47 | Volume | 240,000 |
Register now for FREE live Silence Therapeutics share prices, Silence Therapeutics stock quotes, charts, trades and FREE Silence Therapeutics company fundamentals, market news and much much more. Why not upgrade to a premium service and get Silence Therapeutics Level 2 Data, indepth research tools and investor commentary for Silence Therapeutics (SLN) and other London Stock Exchange equities.
Silence Therapeutics Share Price Chart
Register now for FREE Silence Therapeutics share price charts
Silence Therapeutics Share Price Information
| Name | Silence Therapeutics | Epic | SLN |
|---|---|---|---|
| Activites | Ribonucleic Acid Interference accounted for 99% of 2008 revenues and Immunotherapy, 1% | Reuters | SLN.L |
| ISIN | GB0008433350 | Google Finance | LON:SLN |
| Share Price (p) | 1.58 | Prev. Share Price (p) | 1.58 |
|---|---|---|---|
| Shares in Issue (m) | 577 | Market Cap (£m) | 8 |
| PE Ratio (x) | -1.81 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | |
| EPS (p) | -1.20 | PEG |
Register now for FREE Silence Therapeutics company fundamentals
Silence Therapeutics Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 03/10/2011 | BUY | Thomas Christely | RES | 1,662,162 |
| 03/10/2011 | BUY | Max Herrmann | FD | 1,114,864 |
| 15/02/2010 | BUY | Annette Clancy | NED | 68,284 |
| 15/02/2010 | BUY | Jerry Randall | CH | 70,000 |
| 22/10/2008 | BUY | Jerry Randall | CH | 40,000 |
Silence Therapeutics Company News
FLASH: Silence Therapeutics announces new data from Atu027 trial
Story provided by StockMarketWire.com
New data from Phase I trial with Atu027
FOR IMMEDIATE RELEASE Atu027, a First in Class RNAi Therapy, Demonstrates Potential Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid...
Publication of 2011 Annual Report and Notice of...
FOR IMMEDIATE RELEASE Publication of 2011 Annual Report and Notice of AGM London, May 14, 2012 - Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, announces that it has today published and sent to shareholders the Annual...
More Silence Therapeutics Company News >>
Register now for FREE Silence Therapeutics company news
Silence Therapeutics Share Price Discussions
Silence Therapeutics (SLN)
SILENCE THERAPEUTICS plc ("Silence Therapeutics" or "the Group") INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2007 London, UK, 28 September 2007 - Silence Therapeutics plc (London...
Register now for FREE Silence Therapeutics share price discussions